Geneva – Addex Therapeutics, announced that Janssen Research & Development, LLC, on behalf of Janssen Pharmaceuticals, Inc., has completed enrollment of 120 patients in a multicenter, double-blind, Phase 2 study of ADX71149 in adults with major depressive disorder who are also suffering anxiety symptoms.
The multicenter, double-blind, placebo-controlled study to evaluate the efficacy and overall safety and tolerability of ADX71149 (Clinicaltrials.gov ref. NCT01582815) is being conducted as an adjunctive treatment to an antidepressant in 120 adults with major depressive disorder with anxiety symptoms and partial response to SSRI/SNRI (HDRS ≥ 18 and Anx/Som Factor ≥ 7). Oral ADX71149 is being administered twice-daily at doses ranging from 25mg to 150mg.